Skip to content
Sign in
Venture capitalBacked 1 network startup

LYVA Labs

Liverpool investor with no profile in our data; participated in Ocuwell's 2025 seed.

Liverpool, United Kingdom
Ticket
—Not published
Assets under management
—
Founded
—
Stages
—
Network startups backed
1
Co-investors
2most often with Deepbridge Capital

How they invest

Unknown; one UK health seed deal.

Stage and ticket

Observed at seed.

Geography

United Kingdom (Liverpool).

What makes them say yes

  • UK health deep tech (inferred)
  • Co-investment with Northern Gritstone
  • Seed

Red flags

  • No published thesis, ticket or stage policy in our data — any approach is a cold qualification call
  • Pitching outside the single sector signal visible in its known deal

Sectors

Not published

Stages

Not published

Geographies

Not published

How to approach

Ask Ocuwell for an introduction.

Portfolio

1 network startup · no other company

Ocuwell alongside Northern Gritstone and Deepbridge.

Gaps in the portfolio

  • Unknown thesis

Network startups

  • Ocuwell LimitedSWC 2026 Finalist

    University of Liverpool spin-off making corneal topography portable with OCUTOP, a handheld device matching reference machines.

    United Kingdom · MedTech & devices

Network startups that fit

3 analysed

UK/Bulgarian start-up turning top experts into on-premise “AI twins” for training and know-how retention in nuclear, pharma and defense.

UK pre-seed AI knowledge management — UK company.

25%confidence

Evidence from the records

  • “Ocuwell”
  • “AI agents for knowledge management / corporate training”
  • “Six anonymized use cases (global school chain, mining, telecom, pharma, software publisher, training provider)”
Intro path
Founder-to-founder intro via Ocuwell Limited (network portfolio company of LYVA Labs).
First step
Qualify via Ocuwell.

Tampere spin-off building scalable iPSC-derived corneal cell therapy for limbal stem cell deficiency, targeting first clinical trials around 2027.

Finnish corneal therapy — eye-health adjacency to Ocuwell, non-UK.

15%confidence

Evidence from the records

  • “Ocuwell”
  • “Ophthalmic cell therapy (cornea)”
  • “Corneal cell therapy at preclinical stage, clinical trials targeted around 2027”
Intro path
Founder-to-founder intro via Ocuwell Limited (network portfolio company of LYVA Labs).
First step
Low priority.

Sydney medtech designing JUNO, a pocket-sized tankless oxygen concentrator for chronic respiratory patients, in clinical development with US partners.

Australian portable oxygen — medtech, non-UK.

15%confidence

Evidence from the records

  • “Ocuwell”
  • “Portable oxygen therapy”
  • “JUNO device in clinical development, not approved by the FDA/TGA ("early access" waiting list)”
Intro path
Founder-to-founder intro via Ocuwell Limited (network portfolio company of LYVA Labs).
First step
Low priority.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai.

Co-investors

Most often with Deepbridge Capital and Northern Gritstone

Sources

  1. 1cbinsights.com/company/ocuwell/financials

Profile compiled from public sources. Unknown fields are left empty rather than estimated.